InsiderTrades.com logo

KALV Insider Trading

Insider Ownership Percentage: 10.50%
Insider Buying (Last 12 Months): $2,162,146.35
Insider Selling (Last 12 Months): $1,300,246.77

KalVista Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

KalVista Pharmaceuticals Share Price & Price History

Current Price: $11.09
Price Change: ▼ Price Decrease of -0.06 (-0.54%)
As of 04/2/2025 05:00 PM ET

This chart shows the closing price history over time for KALV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$11.15Closing price on 04/01/25:

SEC Filings (Institutional Ownership Changes) for KalVista Pharmaceuticals (NASDAQ:KALV)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KALV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$111Mbought$21MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More on KalVista Pharmaceuticals

Today's Range

Now: $11.09
Low: $10.84
High: $11.49

50 Day Range

MA: $10.68
Low: $8.56
High: $12.60

52 Week Range

Now: $11.09
Low: $7.30
High: $15.50

Volume

918,573 shs

Average Volume

388,847 shs

Market Capitalization

$551.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Who are the company insiders with the largest holdings of KalVista Pharmaceuticals?

KalVista Pharmaceuticals' top insider investors include:
  1. Venrock Healthcare Capital Par (Major Shareholder)
  2. Benjamin L Palleiko (CEO)
  3. Thomas Andrew Crockett (CEO)
  4. Benjamin L Palleiko (CFO)
  5. Paul K Audhya (Insider)
  6. Christopher Yea (Insider)
  7. Edward P Feener (Insider)
  8. Albert Cha (Director)
Learn More about top insider investors at KalVista Pharmaceuticals.